These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Tacrine treatment of Alzheimer's disease: many expectations, few certainties. Malaguarnera M; Pistone G; Vinci M; Motta M; di Fazio I; Rampello L Neuropsychobiology; 1998 Nov; 38(4):226-31. PubMed ID: 9813462 [TBL] [Abstract][Full Text] [Related]
25. Tetrahydroaminoacridine in Alzheimer's disease. Walsh AC BMJ; 1989 Jun; 298(6687):1579. PubMed ID: 2503129 [No Abstract] [Full Text] [Related]
26. Tacrine and lecithin in Alzheimer's disease. BMJ; 1990 Apr; 300(6729):939-40. PubMed ID: 2337722 [No Abstract] [Full Text] [Related]
27. [Tetrahydroaminoacridine: a promising 'therapy' for Alzheimer's disease?]. Drukarch B; Stoof JC Ned Tijdschr Geneeskd; 1988 Oct; 132(40):1833-5. PubMed ID: 3185771 [No Abstract] [Full Text] [Related]
28. Tacrine in Alzheimer's disease. Levy R Lancet; 1989 Aug; 2(8658):329. PubMed ID: 2569126 [No Abstract] [Full Text] [Related]
29. Therapeutic trials using tacrine and other cholinesterase inhibitors. Gamzu ER; Thal LJ; Davis KL Adv Neurol; 1990; 51():241-5. PubMed ID: 2403716 [TBL] [Abstract][Full Text] [Related]
30. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease. Gustafson L Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836 [TBL] [Abstract][Full Text] [Related]
31. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955 [TBL] [Abstract][Full Text] [Related]
33. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. Summers WK; Majovski LV; Marsh GM; Tachiki K; Kling A N Engl J Med; 1986 Nov; 315(20):1241-5. PubMed ID: 2430180 [TBL] [Abstract][Full Text] [Related]
34. Tacrine, a drug with therapeutic potential for dementia: post-mortem biochemical evidence. Francis PT; Bowen DM Can J Neurol Sci; 1989 Nov; 16(4 Suppl):504-10. PubMed ID: 2572313 [TBL] [Abstract][Full Text] [Related]
35. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817 [TBL] [Abstract][Full Text] [Related]
36. Alternatives in the treatment of memory loss in patients with Alzheimer's disease. Volger BW Clin Pharm; 1991 Jun; 10(6):447-56. PubMed ID: 2065522 [TBL] [Abstract][Full Text] [Related]
37. THA and Alzheimer's disease. Hayward L; Brodaty H Aust N Z J Psychiatry; 1987 Dec; 21(4):618-9. PubMed ID: 3449055 [No Abstract] [Full Text] [Related]
38. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. Little A; Levy R; Chuaqui-Kidd P; Hand D J Neurol Neurosurg Psychiatry; 1985 Aug; 48(8):736-42. PubMed ID: 3897460 [TBL] [Abstract][Full Text] [Related]
39. Tacrine: first drug approved for Alzheimer's disease. Crismon ML Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566 [TBL] [Abstract][Full Text] [Related]
40. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Minthon L; Gustafson L; Dalfelt G; Hagberg B; Nilsson K; Risberg J; Rosén I; Seiving B; Wendt PE Dementia; 1993; 4(1):32-42. PubMed ID: 8358504 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]